AbbVie Inc. expects its fourth-quarter 2023 earnings to include acquired IPR&D and milestones expense of $282 million, which will have an unfavorable impact on diluted earnings per share.
AI Assistant
ABBVIE INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.